The Impact of Reducing Cardiovascular Medication Copayments on Health Spending and Resource Utilization  by Choudhry, Niteesh K. et al.
Journal of the American College of Cardiology Vol. 60, No. 18, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Health Services Research
The Impact of Reducing
Cardiovascular Medication Copayments
on Health Spending and Resource Utilization
Niteesh K. Choudhry, MD, PHD,* Michael A. Fischer, MD, MS,* Jerry L. Avorn, MD,*
Joy L. Lee, MS,* Sebastian Schneeweiss, MD, SCD,* Daniel H. Solomon, MD, MPH,*†
Christine Berman, BSN, MPH,‡ Saira Jan, MS, PHARMD,§ Joyce Lii, MA, MS,*
John J. Mahoney, MD, MPH,‡ William H. Shrank, MD, MSHS*
Boston, Massachusetts; Stamford, Connecticut; and Newark, New Jersey
Objectives The aim of this study was to evaluate the impact of reductions in statin and clopidogrel copayments on cardio-
vascular resource utilization, major coronary events, and insurer spending.
Background Copayments are widely used to contain health spending but cause patients to reduce their use of essential car-
diovascular medications. Reducing copayments for post–myocardial infarction secondary prevention has benefi-
cial effects, but the impact of this strategy for lower risk patients and other drugs remains unclear.
Methods An evaluation was conducted of health care spending and resource use by a large self-insured employer that
reduced statin copayments for patients with diabetes or vascular disease and reduced clopidogrel copayments
for all patients prescribed this drug. Eligible individuals in the intervention company (n  3,513) were compared
with a control group from other companies without such a policy (n  49,803). Analyses were performed using
segmented regression models with generalized estimating equations.
Results Lowering copayments was associated with significant reductions in rates of physician visits (relative change: sta-
tin users 0.80; 95% confidence interval [CI]: 0.57 to 0.98; clopidogrel users: 0.87; 95% CI: 0.59 to 0.96) and
hospitalizations and emergency department admissions (relative change: statin users 0.90; 95% CI: 0.80 to
0.92; clopidogrel users: 0.89; 95% CI: 0.74 to 0.90) although not major coronary events. Patient out-of-pocket
spending for drugs and other medical services decreased (relative change: statin users 0.79; 95% CI: 0.75 to
0.83; clopidogrel users 0.74; 95% CI: 0.66 to 0.82). Providing more generous coverage did not increase
overall spending (relative change: statin users 1.03; 95% CI: 0.97 to 1.09; clopidogrel users 0.94; 95% CI:
0.87 to 1.03).
Conclusions Lowering copayments for statins and clopidogrel was associated with reductions in health care resource use and
patient out-of-pocket spending. The policy appeared cost neutral with respect to overall health spending.
(J Am Coll Cardiol 2012;60:1817–24) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.050Nonadherence to cardiovascular medication is exceptionally
common and results in preventable morbidity, mortality,
and health spending (1). Reducing patient copayments for
From the *Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham
and Women’s Hospital and Harvard Medical School, Boston, Massachusetts;
†Division of Rheumatology, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, Massachusetts; ‡Pitney Bowes Inc.,
Stamford, Connecticut; and the §Horizon Blue Cross Blue Shield of New Jersey,
Newark, New Jersey. This study was supported by The Commonwealth Fund, a
national, private foundation based in New York City that supports independent
research on health care issues and makes grants to improve health care practice and
policy. The views presented here are those of the authors and not necessarily those of
The Commonwealth Fund or its directors, officers, or staff members. Drs. Choudhry,
Avorn, Schneeweiss, and Shrank have received research support through an unre-
stricted grant to the Brigham and Women’s Hospital from Aetna, Inc., for a trialhighly effective, evidence-based therapies has been proposed as a
method of stimulating greater adherence that may also reduce
health spending (2). This strategy has been met with particular
evaluating the impact of cost-sharing reductions on cardiovascular outcomes, and from CVS
Caremark, to study medication adherence. Dr. Choudhry is a consultant to Mercer Health and
Benefits, Inc; and has received research grants from the Commonwealth Fund and the Robert
Wood Johnson Foundation. Dr. Schneeweiss is a consultant to WHISCON, LLC and Booz
& Co. Dr. Mahoney is on the speaker’s bureau for Merck. Dr. Shrank has received research
grants from Lilly, Teva, and the National Association of chain drug stores; and is a consultant
on research methodology to United Healthcare. Ms. Berman is an employee of Pitney Bowes
Inc. Dr. Jan is an employee of Horizon Blue Cross Blue Shield of New Jersey. Dr. Mahoney
was formerly an employee of Pitney Bowes Inc; and is on the Speakers’ Bureau for Merck. All
other authors have reported that they have no relationships relevant to the contents of this
paper to disclose.
Manuscript received May 9, 2012; accepted June 18, 2012.
1818 Choudhry et al. JACC Vol. 60, No. 18, 2012
Impact of Reducing Statin and Clopidogrel Copayments October 30, 2012:1817–24enthusiasm from employers and
health plans throughout the United
States. (3). The Patient Protection
and Affordable Care Act, passed in
March 2010 (4), calls for the cre-
ation of guidelines to facilitate the
broader use of this strategy, which is
generally called value-based insur-
ance design or evidence-based plan design (5).
See page 1825
The existing evidence supports the ability of copayment
reductions to increase essential medication use (6), and
economic models suggest that these changes in adherence
should be associated with meaningful improvements in
health and reductions in resource utilization and could
consequently lower overall health spending (2,7–9). How-
ever, the empirical research evaluating the impact of actual
medication copayment reductions on these outcomes is
extremely limited (10,11).
The recently published MI FREEE (Post–Myocardial
Infarction Free Rx Event and Economic Evaluation) trial
demonstrated that lowering copayments for statins, beta-
blockers, and renin-angiotensin system antagonists pre-
scribed to patients recently discharged after myocardial
infarction improved adherence and reduced rates of major
vascular events (although not revascularization) without
increasing overall health spending (12). However, the trial
enrolled high-risk patients, and thus the generalizability of
the results to other patient groups or other classes of
evidence-based drugs is unclear.
A policy change introduced by a large Fortune 500 creates
a natural experiment and the opportunity to help fill this
knowledge gap. Pitney Bowes eliminated copayments for
statins for patients with diabetes or patients receiving
treatment for vascular disease and lowered them for clopi-
dogrel among all patients prescribed this drug (13). Intro-
duction of this policy resulted in improvements in statin and
clopidogrel adherence of 3 and 4 percentage points, respec-
tively (13). We evaluated whether this benefit design change
also affected cardiovascular resource utilization, major cor-
onary events, and insurer spending.
Methods
Setting and design. We used an interrupted time-series
design with a concurrent control group to evaluate the effect
of reducing copayments for cardiovascular medications on
rates of medication filling, resource utilization, major coro-
nary events, and spending. This method compares actual
post-policy outcome rates with those that would have been
expected if pre-policy outcomes were extrapolated into the
future; the analysis also adjusts for trends in a comparison
Abbreviations
and Acronyms
CI  confidence interval
ICD-9  International
Classification of Diseases-
Ninth Revisionpopulation for whom copayments were not changed.The intervention group was drawn from employees and
retirees of Pitney Bowes. The company provides pharmacy
coverage using a 3-tier coinsurance design; beneficiaries also
have access to an Internet-based health portal that contains
information on chronic disease awareness and treatment as
well as a voluntary disease management program. These
programs were introduced several years before the January 1,
2007 copayment reductions, and the company did not
introduce any new disease management programs or other-
wise change their benefits structure during the study period.
Copayments for nondrug services also remained constant
during this time period. For example, copayments for
primary care physician office visits among Pitney Bowes
beneficiaries were $20 in both 2006 and 2007.
The control group consisted of employees of other
companies who were insured by Horizon Blue Cross Blue
Shield of New Jersey, the largest insurer in New Jersey.
Similar to Pitney Bowes, Horizon offers disease manage-
ment programs for patients with chronic diseases but did
not introduce any new programs during the study period or
change copayments for the medications being studied.
Pitney Bowes and Horizon both use the same pharmacy
benefit manager.
We combined complete paid pharmacy and medical
services claims data to create a relational database consisting
of all filled prescriptions, procedures, inpatient and outpa-
tient physician encounters, hospitalizations, long-term care
admissions, and deaths for all patients studied. All traceable
person-specific identifying factors were transformed into
anonymous, coded study numbers to protect subjects’ pri-
vacy. The institutional review board of Brigham and Wom-
en’s Hospital approved this study.
Cohort eligibility. We created separate cohorts to study
copayment reductions for statins and clopidogrel based on
methods we have described previously (13). The statin
cohort consisted of patients who filled prescriptions for any
medication in this class between January 1, 2006, and
December 31, 2007. Because statin copayments were elim-
inated only for patients with diabetes or vascular disease, we
restricted both the intervention and the control groups to
patients who fulfilled these eligibility criteria used by Pitney
Bowes. Specifically, we included only patients who had 1 or
more claim for a 14-day supply of a diabetes medication
or equipment (test strips or kits, insulin injection devices,
syringes, needles, lancets) or (as evidence of vascular disease)
a beta-blocker (including combination pills) or a platelet
inhibitor (clopidogrel, ticlopidine, dipyridamole, or cilosta-
zol) in the 6-month period before January 1, 2007. In
measuring medication use outcomes, we did not consider
users of combination atorvastatin-amlodipine (Caduet;
Pfizer Inc., New York, New York), because this medication
was not subject to the copayment reduction, but we included
users of all other combination statin products.
The clopidogrel cohort consisted of patients who filled
prescriptions for this drug between January 1, 2006, and
December 31, 2007. Because clopidogrel copayments were
t
r
b
c
c
e
b
b
C
a
c
c
f
3
b
T
s
m
h
t
c
1819JACC Vol. 60, No. 18, 2012 Choudhry et al.
October 30, 2012:1817–24 Impact of Reducing Statin and Clopidogrel Copaymentsreduced for all patients prescribed this drug (i.e., not only
those who fulfilled specific clinical criteria), no additional
inclusion or exclusion criteria were applied to this cohort.
Patients entered both the statin and clopidogrel cohorts
on the dates of their first medication fills after January 1,
2006, and were followed until they died or lost insurance
eligibility or the study period ended. Patients who were
eligible for copayment reductions for both medication
classes appeared in both cohorts.
Outcomes. In both the intervention group and the control
group, we measured monthly rates of medication filling
before and after the introduction of the new copayment
policy for those defined as eligible for reduced copayments.
We also measured resource utilization, including coronary
events. Resource use consisted of emergency department
admissions, hospitalizations, and physician visits for all
causes. Major cardiovascular events were defined on the
basis of validated diagnosis and procedure codes as hospi-
talizations for any of the following conditions: acute myo-
cardial infarction (International Classification of Diseases-
Ninth Revision [ICD-9], codes 410.x [except 410.x2] as the
principal or secondary diagnosis with a length of stay of 3
days and 180 days), unstable angina (ICD-9 codes 411.x
as the principal diagnosis), percutaneous coronary interven-
tion (ICD-9 code 36.01, 36.02, 36.05, 36.06, 36.07, or
36.09), and coronary bypass surgery (ICD-9 codes 36.1x
and 36.2x; Current Procedural Terminology, Fourth Edi-
tion, codes 33510 to 33536, 33545, and 33572).
We assessed the policy change’s impact on patient,
insurer, and combined patient and insurer spending. Spend-
ing was categorized into medical services (i.e., physician
visits, emergency department admissions, hospitalizations,
and outpatient procedures), prescription drugs, and the
combination of these 2 (i.e., total spending) on the basis of
the paid amounts appearing in the insurers’ claims data.
Patient spending on prescription drugs was calculated using
the sum of monthly copayments and coinsurance amounts.
Monthly rates of all outcomes were standardized to
30-day intervals by dividing outcome rates by the number
of days in the month (or the number of days the patients
was eligible in the month) and then multiplying this
amount by 30.
Covariates. We assessed several patient characteristics as of
he date of cohort entry, including age, sex, income, and
ace. Data on socioeconomic status and race were obtained
y linking ZIP codes of residences with data from the U.S.
ensus, which specified the median income and racial
omposition of the geographic population associated with
ach ZIP code. Income and race were dichotomized as
eing greater or less than the median income or percent of
lack residents, respectively, for the patients in our cohort.
omorbidities were assessed on the basis of medical service
nd pharmacy claims from the 12-month period before
ohort entry and included coronary artery disease (ICD-9
odes 410.x to 414.x, 429.2, and V45.81), congestive heart
ailure (ICD-9 codes 428.x), diabetes (ICD-9 codes 250.x), chypertension (ICD-9 codes 401.x to 404.x), Charlson co-
morbidity score (5 or 5), number of hospitalizations
(4 or4), and number of prescription medications (4 or
4) (14).
Statistical analysis. We began our analyses by plotting
monthly medication filling resource use, clinical outcomes,
and spending for the intervention and control groups before
and after the new policy went into effect. We evaluated
whether the policy change was associated with changes in
the proportion of eligible patients who filled in a given
month using generalized linear models. Our regression
models included a constant term, a linear time trend (which
measures the pre-intervention slope), a binary indicator for
exposure (i.e., intervention vs. control), and a binary indi-
cator for the post-intervention time period. Intervention
effects were assessed with the interaction term between
exposure and the post-intervention time period parameter.
We then used patient-level segmented regression to
quantitatively evaluate whether the benefit design change
was associated with changes in resource use. In these
models, repeated observations were made on patients in
each month. Thus, to control for correlated error terms, we
used generalized estimating equations with a first-order
autoregressive covariance structure, adjusting for the cova-
riates listed previously. Because of the skewed nature of
resource use and spending data, we used a log link function
with variances proportional to the mean (i.e., Poisson
distributed errors) (15). As a specification check, we also
modeled costs with an identity link function and gamma
distributed errors. These analyses yielded results very similar
to our primary analysis (data not shown). We also evaluated
the impact of the copayment policy after including a
3-month transition period for policy adoption, beginning 1
month before and lasting 2 months after January 1, 2007.
We also repeated our analyses in those patients who had
initiated the statin or clopidogrel therapy before January
1, 2007, to evaluate the impact of the policy only on
“prevalent users” rather than those patients who began
therapy in response to it. These analyses yielded virtually
identical results to those of the primary analyses (data not
shown).
Results
The study groups consisted of 2,830 patients who were
eligible for copayment reductions (n  2,051 statin users
and n  779 clopidogrel users) and 49,801 controls (n 
8,174 statin users and n  11,627 clopidogrel users). The
aseline characteristics of these patients are presented in
able 1. Compared with controls, patients in the reduced
tatin copayment group were older, were more likely to be
ale, had lower incomes, and were less likely to have
ypertension but were similar with regard to other charac-
eristics, including race and the presence of other clinical
omorbidities. Differences between the clopidogrel reduced
opayment group and controls were more marked: interven-
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white race, and to have coronary artery disease, diabetes,
hypertension; and used more medications in the year prior to
cohort inclusion but were similar with regard to income status,
Charlson score, and the number of past hospitalizations.
In 2006, the year before the intervention began, statin
and clopidogrel copayments were higher in the intervention
group than in the control group (mean monthly statin
copayment $24.18 vs. $11.80, mean monthly clopidogrel
copayment $17.22 vs. $10.65) (see Table 1). The policy
change produced substantial reductions in copayments in
the intervention cohort (mean monthly statin copayment
Patient CharacteristicsTable 1 Patient Characteristics
Characteristic
Stati
Intervention
(n  2,051) (n
Demographics
Age (yrs) 58.8 10.1 5
Women 36.1%
Income ($) 56,625 21,577 58,
Black race 11.5%
Comorbid conditions
Coronary artery disease 26.3%
Congestive heart failure 1.8%
Hypertension 50.0%
Diabetes 36.2%
Charlson comorbidity score 1.0 1.3
Medication use in prior year 9.0 6.1
Hospitalizations in prior year 0.2 0.6
Monthly medication copayments for study class* ($)
Year before copayment reduction 24.18 21.31 11
Year after copayment reduction 0.60 3.82 11
Follow-up time, months 19.7 5.8 1
Values are mean  SD or as %. *Statins or clopidogrel as appropriate.
Figure 1 Statin Filling Rates
Statin filling rates before and after copayments were reduced compared with contr$0.60, mean monthly clopidogrel copayment $8.86).
Among controls, monthly copayments increased by $0.15
for statins and by $3.78 for clopidogrel.
Medication use. Rates of monthly statin and clopidogrel
filling among intervention and control patients are pre-
sented in Figures 1 and 2, respectively. Adjusting for
baseline trends, the new copayment policy resulted in an
increase in the monthly rate of statin filling of 7.1 percent-
age points (95% confidence interval [CI]: 5.3 to 8.8 per-
centage points; p 0.001). Similarly, the rate of clopidogrel
filling increased by 5.9 percentage points (95% CI: 3.5 to
8.2 percentage points; p  0.001).
s Clopidogrel Users
rol
,174) p Value
Intervention
(n  779)
Control
(n  11,627) p Value
7.3 0.0001 67.5 12.7 54.5 7.0 0.0001
% 0.01 37.6% 28.8% 0.0001
19,993 0.0001 54,715 21,886 57,286 19,458 0.0004
% 0.37 10.2% 12.3% 0.004
% 0.29 60.6% 43.8% 0.0001
% 0.86 1.8% 2.4% 0.28
% 0.0001 55.5% 46.4% 0.0001
% 0.12 12.6% 9.9% 0.02
1.3 0.72 3.3 3.3 0.0001
6.6 0.21 12.6 9.2 10.3 9.4 0.0001
0.5 0.001 0.4 0.7 0.3 0.7 0.0001
11.46 0.0001 17.22 16.74 10.65 10.48 0.0001
11.44 0.0001 8.86 6.97 14.43 13.38 0.0001
6.3 0.0001 15.0 7.8 16.5 7.4 0.0001n User
Cont
 38
3.8
39.8
263
11.9
25.3
1.8
59.5
34.5
1.0
9.1
0.2
.80
.95
8.4ols.
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ering copayments on resource utilization and major coro-
nary events is presented in Table 2. Compared with con-
trols, the new policy was associated with statistically
significant reductions in rates of physician visits and hospi-
talizations and emergency department admissions for pa-
tients in both study cohorts. For example, rates of physician
visits (relative change: statin users 0.80; 95% CI: 0.57 to
0.98; clopidogrel users 0.87; 95% CI: 0.59 to 0.96) de-
creased with copayment reduction. Eliminating copayments
was also associated with reductions in hospitalization or
emergency department admission in both cohorts (relative
change: statin users 0.90; 95% CI: 0.80 to 0.92; clopidogrel
users 0.89; 95% CI: 0.74 to 0.90). Rates of major coronary
events or coronary revascularization procedures were not
significantly changed (Table 2). Results among the sub-
group of patients who had initiated therapy before the start
of the new copayment policy were virtually identical.
Spending. Monthly rates of insurer spending for statins
and clopidogrel users before and after copayment reduction
are shown in Figures 3 and 4, respectively. For patients
taking statins, the new copayment policy was associated
with significant increases in insurer prescription drug spend-
ing (relative change 1.14; 95% CI: 1.10 to 1.19) but no
significant changes in insurer medical spending (relative
change 1.02; 95% CI: 0.90 to 1.16) (Table 3). Combined
Figure 2 Clopidogrel Filling Rates
Clopidogrel filling rates before and after copayments were reduced compared with
Impact of Copayment Reductions on Resource UtilizationTable 2 Impact of Copayment Reductions on Resource Utilizat
Cohort Impact of Copayment Reduction* P
Statin Relative change in level of resource use (95% CI) 0
Clopidogrel Relative change in level of resource use (95% CI) 0
*Adjusted for age, sex, income, race, coronary artery disease, congestive heart failure, diabetes, hy
in the year before cohort entry.
CI  confidence interval.insurer pharmacy and medical spending for the statin cohort
increased by 8% (relative change 1.08; 95% CI: 1.01 to
1.15). In contrast, patient out-of-pocket spending for pre-
scription drugs and other nondrug services decreased sig-
nificantly (relative change 0.79; 95% CI: 0.75 to 0.83), and
therefore overall, combined insurer and patient spending for
drugs and medical services was not significantly changed
(relative change 1.03; 95% CI: 0.97 to 1.09). Results among
clopidogrel users (Table 3) and the subgroup of patients
who had initiated therapy before the start of the new
copayment policy (data not shown) were very similar.
Discussion
Programs to enhance cardiovascular medication adherence
by strategically reducing patient cost sharing are believed to
hold much promise for improving cardiovascular quality in a
cost-efficient manner (4,13). In keeping with this, the recently
published MI FREEE trial found that eliminating copayments
for statins, beta-blockers, and renin-angiotensin system antag-
onists had beneficial clinical and economic effects among
post–myocardial infarction patients (12). And although the
existing peer-reviewed research supports the ability of this
quality improvement strategy to increase appropriate med-
ication use in a broader range of patients (3,13), the impact
of this approach on cardiovascular health services use and
ls.
an Visits
Hospitalizations or Emergency
Department Admissions
Coronary Events or
Revascularization
57–0.98) 0.90 (0.80–0.92) 1.19 (0.22–2.21)
59–0.96) 0.89 (0.74–0.90) 1.10 (0.66–2.02)
ion, Charlson comorbidity score, and the number of hospitalizations and prescription medicationscontroion
hysici
.80 (0.
.87 (0.
pertens
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vascular drugs, specifically clopidogrel, has received limited
attention. In our analysis, we found that lowering statin and
clopidogrel copayments increased medication filling rates;
reduced rates of physician visits, hospitalizations, and emer-
gency department admissions; reduced patient out-of-
pocket spending for drugs and other medical services; and
was cost neutral with regard to overall health spending,
although the reduction did not have a significant impact on
rates of vascular events or revascularization.
Figure 3 Insurer Spending for Statin Users
Insurer pharmacy, medical, and total spending for statin users before and after co
Figure 4 Insurer Spending for Clopidogrel Users
Insurer pharmacy, medical, and total spending for clopidogrel users before and afThe hope that copayment reductions for cardiovascular
medications will reduce health care consumption and costs
has, thus far, been based largely on data from economic
models (8,9). Using formal econometric techniques applied
to real-world data in the present study, we observed reduc-
tions in resource use. In light of the results of MI FREEE,
the magnitude of the changes we observed would plausibly
be expected from the previously reported modest but sig-
nificant improvements in adherence resulting from this
policy (13). However, we found that these beneficial
nts were reduced compared with controls.
ayments were reduced compared with controls.paymeter cop
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combined patient and insurer spending or clinical event
rates. This may have been because the policy had only a
small effect on absolute event rates, as the clinical impact of
modest increases in preventive cardiovascular medication
use for lower risk patients may take longer to become
evident than the time period we evaluated. The lack of effect
may be especially pronounced for patients who became new
statin users in response to the reduced copayments, because
such patients may be less likely to have an event in the first
12 months of statin therapy. Furthermore, even though
clopidogrel may have clinical effects shortly after its discon-
tinuation in patients with acute coronary disease (16), this
therapy is often used by lower risk patients who derive less
benefit (17). The design of the new policy may have made
this particularly likely, because clopidogrel users were not
required to meet specific clinical criteria to be eligible for the
copayment reduction. Similarly, the statin copayment change
targeted patients with coronary artery disease or diabetes,
the former of which was assessed on the basis of beta-
blocker or antiplatelet use. These agents may be prescribed
for noncoronary indications, and thus the policy’s lack of
clinical benefit could possibly have been due to the inclusion
of statin users who were at particularly low clinical risk.
Alternatively, as observed in MI FREEE, the lack of a
clinical effect may have been attributable to the policy’s
neutral impact on revascularization procedures, which are
sometimes done for discretionary indications (18).
Most coverage changes involve a trade-off between the
richness of benefits provided to patients and the associated
costs incurred by third-party payers. In this context, con-
cerns about the short-term cost implications may make
payers reluctant to reduce patient cost sharing even for
therapies such as statins that have ample data demonstrating
their long-term cost-effectiveness (3). Our finding that
reducing copayments for statins and clopidogrel was cost
neutral in the first 12 months of the policy’s implementation
should be reassuring and may be a sufficiently attractive
outcome to promote the greater use of this strategy, espe-
cially given that there are few, if any, quality improvement
interventions that actually reduce health spending. More
important, very consistent with results from MI FREEE,
patient out-of-pocket spending decreased by 35% and 28%,
Impact of Copayment Reductions on Changes in Patient, Insurer, aTable 3 Impact of Copayment Reductions on Changes in Patie
Cohort Type* Pharmacy Spending (95% C
Statin Insurer 1.14 (1.10–1.19)
Patient 0.65 (0.62–0.68)
Combined 1.06 (1.02–1.10)
Clopidogrel Insurer 0.93 (0.87–1.00)
Patient 0.72 (0.67–0.76)
Combined 1.03 (0.98–1.08)
Estimates represent relative spending changes. *Adjusted for age, sex, income, race, coronary arte
of hospitalizations and prescription medications in the year before cohort entry.
CI  confidence interval.respectively, among the statin and clopidogrel patients. Thisobservation, in the context of the policy’s overall cost
neutrality, suggest that copayment reductions for cardiovas-
cular drugs could be applied more broadly than only to
post–myocardial infarction patients.
Study limitations. Our results should be interpreted in
light of methodological limitations. First, we performed a
retrospective cohort study using time-series methods adjust-
ing for underlying utilization trends in a comparable pop-
ulation for whom copayments were not reduced. This
technique is considered the strongest quasi-experimental
design (19), and baseline differences in intervention and
controls, even with regard to differences in baseline copay-
ments, should not limit our ability to make valid inferences
about relative changes in outcomes after copayments were
reduced (20). Nevertheless, our analysis is subject to the
possibility that the observed improvements in utilization
were due to other simultaneously occurring events, of which
we were not aware.
Second, our outcome measures relied on administrative
claims that do not contain detailed clinical information such
as cholesterol levels. Therefore, it is possible that unmea-
sured differences between intervention and control patients
could have contributed to our findings.
Third, our sample size was modest, and we are unable to
exclude the possibility that the copayment policy had a small
positive or negative effect on the outcomes we evaluated.
That said, the upper 95% confidence bounds of our point
estimates suggest that any such effects are unlikely to be
extremely large. However, it is possible that we underesti-
mated clinical benefits of the copayment policy. Patients in
the control population who did not start statin or clopi-
dogrel therapy because of financial barriers would not be
included in the control group, and therefore any potentially
avoidable clinical events that occurred in these patients
would not be captured in the analyses.
Conclusions
Despite these limitations, our study provides high-quality
empirical data on the effects of selective copayment reduc-
tions for statins and clopidogrel among a lower risk patient
cohort than evaluated in recently published clinical trial
data. Although these findings do not support the belief that
ombined Pharmacy, Medical, and Total Spendingsurer, and Co bined Pharmacy, Medical, and Total Spending
Medical Spending (95% CI) Total Spending (95% CI)
1.02 (0.90–1.16) 1.08 (1.01–1.15)
0.90 (0.83–0.98) 0.79 (0.75–0.83)
0.99 (0.83–1.18) 1.03 (0.97–1.09)
0.90 (0.78–1.03) 0.96 (0.88–1.05)
0.76 (0.61–0.94) 0.74 (0.66–0.82)
1.14 (0.87–1.50) 0.94 (0.87–1.03)
ase, congestive heart failure, diabetes, hypertension, Charlson comorbidity score, and the numbernd Cnt, In
I)
ry disethis quality improvement strategy will meaningfully reduce
11
1
1
1
1
1
1
1
1
2
1824 Choudhry et al. JACC Vol. 60, No. 18, 2012
Impact of Reducing Statin and Clopidogrel Copayments October 30, 2012:1817–24health care spending, they do suggest overall cost neutrality
and beneficial effects for resource use and thus support the
reduction of evidence-based medication copayments for a
wide range of cardiovascular drugs and patient risk groups.
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